Soluble endoglin and other circulating antiangiogenic factors in preeclampsia
Soluble endoglin and other circulating antiangiogenic factors in preeclampsia
复制标题
DOI：
10.1056/nejmoa055352
复制
发表时间：
2006-09-07
影响因子：
158.5
通讯作者：
Karumanchi, S. Ananth
中科院分区：
文献类型：
--
作者：
Levine, Richard J.;Lam, Chun;Karumanchi, S. Ananth
背景：循环可溶性 fms 样酪氨酸激酶 1 (sFlt1)（一种抗血管生成蛋白）和胎盘生长因子 (PlGF)（一种促血管生成蛋白）的改变似乎与先兆子痫的发病机制有关。由于可溶性内皮糖蛋白（另一种抗血管生成蛋白）与 sFlt1 一起作用，在怀孕大鼠中诱导严重的先兆子痫样综合征，因此我们检查了它是否与女性先兆子痫相关。方法：我们在钙预防先兆子痫试验中对健康未产妇进行了一项巢式病例对照研究。该研究纳入了所有 72 名患有早产先兆子痫（= 37 周）的妇女、120 名患有妊娠期高血压的妇女、120 名产下小于胎龄婴儿的血压正常妇女以及 120 名产下大于胎龄婴儿的血压正常对照组。 结果：在先兆子痫发作前 2 至 3 个月，循环可溶性内皮糖蛋白水平开始显着升高。临床疾病出现后，早产儿先兆子痫女性的平均血清水平为 46.4 ng/mL，而对照组为 9.8 ng/mL（P
Background:Alterations in circulating soluble fms-like tyrosine kinase 1 (sFlt1), an antiangiogenic protein, and placental growth factor (PlGF), a proangiogenic protein, appear to be involved in the pathogenesis of preeclampsia. Since soluble endoglin, another antiangiogenic protein, acts together with sFlt1 to induce a severe preeclampsia-like syndrome in pregnant rats, we examined whether it is associated with preeclampsia in women.Methods:We performed a nested case-control study of healthy nulliparous women within the Calcium for Preeclampsia Prevention trial. The study included all 72 women who had preterm preeclampsia (= 37 weeks), 120 women with gestational hypertension, 120 normotensive women who delivered infants who were small for gestational age, and 120 normotensive controls who delivered infants who were not small for gestational age.Results:Circulating soluble endoglin levels increased markedly beginning 2 to 3 months before the onset of preeclampsia. After the onset of clinical disease, the mean serum level in women with preterm preeclampsia was 46.4 ng per milliliter, as compared with 9.8 ng per milliliter in controls (P